Discount up to 35% for first purchase only this month.
Discount up to 35% for first purchase only this month.
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk, representing the current standard for single-mechanism metabolic peptide research.
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk, representing the current standard for single-mechanism metabolic peptide research. It mimics endogenous GLP-1 with 94% homology but with extended half-life (~165 hours) due to albumin binding via a C-18 fatty di-acid side chain. With extensive Phase 3 data across diabetes (SUSTAIN trials) and obesity (STEP trials), Semaglutide serves as a benchmark comparator for researchers studying newer metabolic peptides including Tirzepatide and Retatrutide.
Purchasers must be 21 years of age or older.
The products shown on this website are intended strictly for laboratory research purposes only and are not for human or animal consumption in any form.